Show
Sort by
-
- Journal Article
- A1
- open access
Targeted AURKA degradation : towards new therapeutic agents for neuroblastoma
-
- Journal Article
- A1
- open access
Mitotic dysregulation at tumor initiation creates a therapeutic vulnerability to combination anti-mitotic and pro-apoptotic agents for MYCN-driven neuroblastoma
-
- Journal Article
- A1
- open access
The feasibility of using liquid biopsies as a complementary assay for copy number aberration profiling in routinely collected paediatric cancer patient samples
-
- Journal Article
- A1
- open access
ALK ligand ALKAL2 potentiates MYCN‐driven neuroblastoma in the absence of ALK mutation
-
- Journal Article
- A1
- open access
A G316A polymorphism in the ornithine decarboxylase gene promoter modulates MYCN-driven childhood neuroblastoma
-
- Journal Article
- A1
- open access
MEIS2 is an adrenergic core regulatory transcription factor involved in early initiation of TH-MYCN-driven neuroblastoma formation
-
- Journal Article
- A1
- open access
From DNA copy number gains and tumor dependencies to novel therapeutic targets for high-risk neuroblastoma
-
Accelerating drug development for neuroblastoma : summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma
-
- Journal Article
- A1
- open access
The ETS transcription factor ETV5 is a target of activated ALK in neuroblastoma contributing to increased tumour aggressiveness
-
DREAM target reactivation by core transcriptional regulators supports neuroblastoma growth